TLC_Tagline EN.png
TLC to Present at 38th Annual JP Morgan Healthcare Conference
January 02, 2020 04:00 ET | TLC
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Jan. 02, 2020 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to...
TLC_Tagline EN.png
TLC Announces First Patient Enrollment in EXCELLENCE Trial Evaluating Single and Repeat Administrations of TLC599
November 27, 2019 04:30 ET | TLC
Phase III clinical trial of TLC599 to recruit 500 patients with moderate to severe symptomatic knee osteoarthritis  Patients can receive two injections of placebo or drugPatient enrollment expected to...
TLC_Tagline EN.png
TLC Announces Completion of US$27 Million Financing
October 24, 2019 05:00 ET | TLC
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Oct. 24, 2019 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to...
TLC_Tagline EN.png
TLC Reports Third Quarter 2019 Financial Results and Provides Business Update
October 22, 2019 06:09 ET | TLC
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Oct. 22, 2019 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to...
TLC_Tagline EN.png
TLC Presents Clinical and Preclinical Data of TLC590 at ANESTHESIOLOGY® Annual Meeting and in International Journal of Nanomedicine
October 21, 2019 05:24 ET | TLC
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Oct. 21, 2019 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company developing novel nanomedicines to...
TLC_Tagline EN.png
TLC Appoints Vincent Chang, PhD, as Vice President of Manufacturing Development
October 20, 2019 04:10 ET | TLC
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Oct. 20, 2019 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company dedicated to the development and...
Absolute Difference of Cartilage Deterioration
TLC to Present Potential Cartilage-Protecting Effects of TLC599 on the Knee at 2019 ACR Annual Meeting
October 07, 2019 04:30 ET | TLC
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Oct. 07, 2019 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company dedicated to the development and...
TLC_Tagline EN.png
TLC Announces Initiation of Phase III Pivotal Clinical Trial of TLC599 for the Treatment of Osteoarthritis Knee Pain
October 01, 2019 04:30 ET | TLC
- Phase II results showed statistically significant pain relief through 24 weeks- Phase III to evaluate efficacy of single and repeated doses up to 52 weeks SOUTH SAN FRANCISCO, Calif. and TAIPEI,...
TLC_Tagline EN.png
TLC to Present Preclinical Data on TLC178 at ESMO 2019
September 23, 2019 05:00 ET | TLC
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Sept. 23, 2019 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152), a clinical-stage specialty pharmaceutical company dedicated to the development and...
TLC_Tagline EN.png
TLC to Present as Panelist among Key Opinion Leaders at the BTIG Pain Management Forum
September 03, 2019 06:04 ET | TLC
SOUTH SAN FRANCISCO, Calif. and TAIPEI, Taiwan, Sept. 03, 2019 (GLOBE NEWSWIRE) -- TLC (Nasdaq: TLC, TWO: 4152) announced today that the Company’s management team has been invited to participate in...